Using RNA sequencing of primary breast tumor samples taken at surgery and with a detection limit of minimum 2% MAF, the overall frequency of ESR1 ET resistance mutations in the population-based SCAN-B cohort was 0.9%, corresponding to 1.1% among the ER-positive tumors. The gene discussed is ESR1; the disease is breast neoplasm.